haematological

"We remain committed to the future discovery of oncology products," a spokesman for AstraZeneca said Monday, noting that AstraZeneca has five oncology products in phase II studies: Olaparib for ovarian and breast cancer, AZD1152 for haematological malignancies, as well as AZD8931, AZD6244, and AZD7762 which are being investigated for solid tumors.

Astra's Prostate-Cancer Drug Fails Trial Sten Stovall 2010

The tragedy of his particular case is that if he had had his sister's kidney, he would have been fine … lymphoma, or indeed any type of haematological cancer, is an absolute contra-indication for transplantation.

Transplant patients given kidneys from donor with cancer 2011

Impact of antifungal prophylaxis on the gastrointestinal yeast colonisation in patients with haematological malignancies.

Mark Hyman, MD: Is Hidden Fungus Making You Ill? 2010

For patients in whom cisplatin cannot be used, carboplatin can be substituted but non-randomised data have shown lower response rates and high rates of haematological toxicity for carboplatin-based combinations, albeit with similar survival figures to patients receiving cisplatin.

Balkinization 2007

For patients in whom cisplatin cannot be used, carboplatin can be substituted but non-randomised data have shown lower response rates and high rates of haematological toxicity for carboplatin-based combinations, albeit with similar survival figures to patients receiving cisplatin.

Balkinization 2007

For patients in whom cisplatin cannot be used, carboplatin can be substituted but non-randomised data have shown lower response rates and high rates of haematological toxicity for carboplatin-based combinations, albeit with similar survival figures to patients receiving cisplatin.

Balkinization 2007

For patients in whom cisplatin cannot be used, carboplatin can be substituted but non-randomised data have shown lower response rates and high rates of haematological toxicity for carboplatin-based combinations, albeit with similar survival figures to patients receiving cisplatin.

Balkinization 2007

For patients in whom cisplatin cannot be used, carboplatin can be substituted but non-randomised data have shown lower response rates and high rates of haematological toxicity for carboplatin-based combinations, albeit with similar survival figures to patients receiving cisplatin.

Balkinization 2007

For patients in whom cisplatin cannot be used, carboplatin can be substituted but non-randomised data have shown lower response rates and high rates of haematological toxicity for carboplatin-based combinations, albeit with similar survival figures to patients receiving cisplatin.

Balkinization 2007

For patients in whom cisplatin cannot be used, carboplatin can be substituted but non-randomised data have shown lower response rates and high rates of haematological toxicity for carboplatin-based combinations, albeit with similar survival figures to patients receiving cisplatin.

Balkinization 2007